-
1
-
-
0020402019
-
Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance
-
6184101 10.1007/BF01806449 1:CAS:528:DyaL38XlslCht7g%3D
-
Jordan VC (1982) Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 2:123-138
-
(1982)
Breast Cancer Res Treat
, vol.2
, pp. 123-138
-
-
Jordan, V.C.1
-
2
-
-
0032537990
-
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
-
9747868 10.1093/jnci/90.18.1371 1:CAS:528:DyaK1cXmtlelurs%3D
-
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1371-1388
-
-
Fisher, B.1
Costantino, J.P.2
Wickerham, D.L.3
Redmond, C.K.4
Kavanah, M.5
Cronin, W.M.6
Vogel, V.7
Robidoux, A.8
Dimitrov, N.9
Atkins, J.10
Daly, M.11
Wieand, S.12
Tan-Chiu, E.13
Ford, L.14
Wolmark, N.15
-
3
-
-
84860328324
-
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)
-
22234519 10.1007/s10549-011-1943-y 1:CAS:528:DC%2BC38XmtlOksr4%3D
-
Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y (2012) Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat 133:227-236
-
(2012)
Breast Cancer Res Treat
, vol.133
, pp. 227-236
-
-
Takei, H.1
Ohsumi, S.2
Shimozuma, K.3
Takehara, M.4
Suemasu, K.5
Ohashi, Y.6
Hozumi, Y.7
-
4
-
-
0037441639
-
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
-
12586795 10.1200/JCO.2003.07.071 1:CAS:528:DC%2BD2cXpsVGrtbs%3D
-
Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606
-
(2003)
J Clin Oncol
, vol.21
, pp. 602-606
-
-
Partridge, A.H.1
Wang, P.S.2
Winer, E.P.3
Avorn, J.4
-
5
-
-
79956104201
-
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
-
20803066 10.1007/s10549-010-1132-4 1:CAS:528:DC%2BC3MXjtFSrtrw%3D
-
Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537
-
(2011)
Breast Cancer Res Treat
, vol.126
, pp. 529-537
-
-
Hershman, D.L.1
Shao, T.2
Kushi, L.H.3
Buono, D.4
Tsai, W.Y.5
Fehrenbacher, L.6
Kwan, M.7
Gomez, S.L.8
Neugut, A.I.9
-
6
-
-
39149107837
-
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer
-
18071188 10.1200/JCO.2006.10.1022
-
Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549-555
-
(2008)
J Clin Oncol
, vol.26
, pp. 549-555
-
-
Owusu, C.1
Buist, D.S.2
Field, T.S.3
Lash, T.L.4
Thwin, S.S.5
Geiger, A.M.6
Quinn, V.P.7
Frost, F.8
Prout, M.9
Yood, M.U.10
Wei, F.11
Silliman, R.A.12
-
7
-
-
0023922814
-
Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile
-
3349495 1:CAS:528:DyaL1cXktVSqurk%3D
-
Lien EA, Solheim E, Kvinnsland S, Ueland PM (1988) Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48:2304-2308
-
(1988)
Cancer Res
, vol.48
, pp. 2304-2308
-
-
Lien, E.A.1
Solheim, E.2
Kvinnsland, S.3
Ueland, P.M.4
-
8
-
-
0020033521
-
Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen
-
7062732 10.1016/0022-4731(82)90137-6 1:CAS:528:DyaL38XktFOgur0%3D
-
Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS (1982) Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16:1-13
-
(1982)
J Steroid Biochem
, vol.16
, pp. 1-13
-
-
Robertson, D.W.1
Katzenellenbogen, J.A.2
Long, D.J.3
Rorke, E.A.4
Katzenellenbogen, B.S.5
-
9
-
-
1842607090
-
Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer
-
15039600 10.1023/B:BREA.0000021050.92539.b0 1:CAS:528: DC%2BD2cXisVWgtbw%3D
-
Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK, Flaws JA (2004) Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat 85:89-97
-
(2004)
Breast Cancer Res Treat
, vol.85
, pp. 89-97
-
-
Gallicchio, L.1
Lord, G.2
Tkaczuk, K.3
Danton, M.4
Lewis, L.M.5
Lim, C.K.6
Flaws, J.A.7
-
10
-
-
37849000864
-
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism
-
17947222 10.1093/annonc/mdm434 1:STN:280:DC%2BD1c%2FgtVGhsQ%3D%3D
-
Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Kisanga ER, Mellgren G, Steen VM, Lien EA (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19:56-61
-
(2008)
Ann Oncol
, vol.19
, pp. 56-61
-
-
Gjerde, J.1
Hauglid, M.2
Breilid, H.3
Lundgren, S.4
Varhaug, J.E.5
Kisanga, E.R.6
Mellgren, G.7
Steen, V.M.8
Lien, E.A.9
-
11
-
-
0035667614
-
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers
-
11829201 10.1007/s002280100273 1:CAS:528:DC%2BD3MXovVWgsrc%3D
-
Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH (2001) The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 57:717-722
-
(2001)
Eur J Clin Pharmacol
, vol.57
, pp. 717-722
-
-
Tamminga, W.J.1
Wemer, J.2
Oosterhuis, B.3
De Zeeuw, R.A.4
De Leij, L.F.5
Jonkman, J.H.6
-
12
-
-
0037094334
-
Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases
-
12034366 10.1016/S0006-2952(02)00994-2 1:CAS:528:DC%2BD38XktVCit7c%3D
-
Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, Watabe T (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP- glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830
-
(2002)
Biochem Pharmacol
, vol.63
, pp. 1817-1830
-
-
Nishiyama, T.1
Ogura, K.2
Nakano, H.3
Ohnuma, T.4
Kaku, T.5
Hiratsuka, A.6
Muro, K.7
Watabe, T.8
-
13
-
-
0742286803
-
Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry
-
14618296 10.1007/s00210-003-0832-2 1:CAS:528:DC%2BD2cXitF2hsQ%3D%3D
-
Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37
-
(2004)
Naunyn Schmiedebergs Arch Pharmacol
, vol.369
, pp. 23-37
-
-
Zanger, U.M.1
Raimundo, S.2
Eichelbaum, M.3
-
14
-
-
0031561408
-
Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype
-
9345314 10.1006/bbrc.1997.7466 1:CAS:528:DyaK2sXmvVKmt7k%3D
-
Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298-304
-
(1997)
Biochem Biophys Res Commun
, vol.239
, pp. 298-304
-
-
Raftogianis, R.B.1
Wood, T.C.2
Otterness, D.M.3
Van Loon, J.A.4
Weinshilboum, R.M.5
-
15
-
-
0032427866
-
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin
-
9871429 10.1016/S0009-9236(98)90055-8 1:CAS:528:DyaK1MXjslWgsg%3D%3D
-
Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ (1998) Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 64:648-654
-
(1998)
Clin Pharmacol Ther
, vol.64
, pp. 648-654
-
-
Kivisto, K.T.1
Villikka, K.2
Nyman, L.3
Anttila, M.4
Neuvonen, P.J.5
-
16
-
-
0025133172
-
Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide
-
2393854 1:CAS:528:DyaK3MXhslWitw%3D%3D
-
Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM (1990) Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50:5851-5857
-
(1990)
Cancer Res
, vol.50
, pp. 5851-5857
-
-
Lien, E.A.1
Anker, G.2
Lonning, P.E.3
Solheim, E.4
Ueland, P.M.5
-
17
-
-
0036793163
-
Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites
-
12419016 10.1080/00498250210158230 1:CAS:528:DC%2BD38XnvFCktbo%3D
-
Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD (2002) Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32:863-878
-
(2002)
Xenobiotica
, vol.32
, pp. 863-878
-
-
Zhao, X.J.1
Jones, D.R.2
Wang, Y.H.3
Grimm, S.W.4
Hall, S.D.5
-
18
-
-
0346602691
-
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
-
14652237 10.1093/jnci/djg108 1:CAS:528:DC%2BD3sXpvVelsbc%3D
-
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 1758-1764
-
-
Stearns, V.1
Johnson, M.D.2
Rae, J.M.3
Morocho, A.4
Novielli, A.5
Bhargava, P.6
Hayes, D.F.7
Desta, Z.8
Flockhart, D.A.9
-
19
-
-
0037032497
-
Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy
-
12419790 10.1093/jnci/94.21.1635 1:CAS:528:DC%2BD38XosFOgsbw%3D
-
Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB (2002) Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94:1635-1640
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1635-1640
-
-
Nowell, S.1
Sweeney, C.2
Winters, M.3
Stone, A.4
Lang, N.P.5
Hutchins, L.F.6
Kadlubar, F.F.7
Ambrosone, C.B.8
-
20
-
-
77953679656
-
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
-
20565970 10.1186/1471-2407-10-313
-
Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, Steen VM, Lien EA (2010) Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10:313-325
-
(2010)
BMC Cancer
, vol.10
, pp. 313-325
-
-
Gjerde, J.1
Geisler, J.2
Lundgren, S.3
Ekse, D.4
Varhaug, J.E.5
Mellgren, G.6
Steen, V.M.7
Lien, E.A.8
-
21
-
-
84877575399
-
CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
-
23580071 10.1007/s10549-013-2511-4 1:CAS:528:DC%2BC3sXnsVWhs78%3D
-
Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB (2013) CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 139:95-105
-
(2013)
Breast Cancer Res Treat
, vol.139
, pp. 95-105
-
-
Teft, W.A.1
Gong, I.Y.2
Dingle, B.3
Potvin, K.4
Younus, J.5
Vandenberg, T.A.6
Brackstone, M.7
Perera, F.E.8
Choi, Y.H.9
Zou, G.10
Legan, R.M.11
Tirona, R.G.12
Kim, R.B.13
-
22
-
-
67651177578
-
Genotype-guided tamoxifen therapy: Time to pause for reflection?
-
19647203 10.1016/S1470-2045(09)70030-0 1:CAS:528:DC%2BD1MXptlals7s%3D
-
Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10:825-833
-
(2009)
Lancet Oncol
, vol.10
, pp. 825-833
-
-
Lash, T.L.1
Lien, E.A.2
Sorensen, H.T.3
Hamilton-Dutoit, S.4
-
23
-
-
80455168584
-
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P1 and P2 clinical trials
-
21880792 10.1158/1078-0432.CCR-11-0860 1:CAS:528:DC%2BC3MXhsVWlsr3O
-
Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M, Batzler A, Costantino JP, Vogel VG, Paik S, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM, Ingle JN, Ames MM (2011) Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res 17:6944-6951
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6944-6951
-
-
Goetz, M.P.1
Schaid, D.J.2
Wickerham, D.L.3
Safgren, S.4
Mushiroda, T.5
Kubo, M.6
Batzler, A.7
Costantino, J.P.8
Vogel, V.G.9
Paik, S.10
Carlson, E.E.11
Flockhart, D.A.12
Wolmark, N.13
Nakamura, Y.14
Weinshilboum, R.M.15
Ingle, J.N.16
Ames, M.M.17
-
24
-
-
80455174466
-
SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
-
21961651 10.2217/pgs.11.97 1:CAS:528:DC%2BC3MXhtlyqtrfN
-
Moyer AM, Suman VJ, Weinshilboum RM, Avula R, Black JL, Safgren SL, Kuffel MJ, Ames MM, Ingle JN, Goetz MP (2011) SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics 12:1535-1543
-
(2011)
Pharmacogenomics
, vol.12
, pp. 1535-1543
-
-
Moyer, A.M.1
Suman, V.J.2
Weinshilboum, R.M.3
Avula, R.4
Black, J.L.5
Safgren, S.L.6
Kuffel, M.J.7
Ames, M.M.8
Ingle, J.N.9
Goetz, M.P.10
-
25
-
-
84859093970
-
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial
-
Breast International Group 1-98 Collaborative G 22395644 10.1093/jnci/djs125 1:CAS:528:DC%2BC38Xksl2rsbo%3D
-
Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G, Breast International Group 1-98 Collaborative G (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441-451
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 441-451
-
-
Regan, M.M.1
Leyland-Jones, B.2
Bouzyk, M.3
Pagani, O.4
Tang, W.5
Kammler, R.6
Dell'Orto, P.7
Biasi, M.O.8
Thurlimann, B.9
Lyng, M.B.10
Ditzel, H.J.11
Neven, P.12
Debled, M.13
Maibach, R.14
Price, K.N.15
Gelber, R.D.16
Coates, A.S.17
Goldhirsch, A.18
Rae, J.M.19
Viale, G.20
more..
-
26
-
-
20544435404
-
Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry
-
16038189 10.1016/j.chroma.2005.01.004 1:CAS:528:DC%2BD2MXlvVemsb0%3D
-
Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA (2005) Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1082:6-14
-
(2005)
J Chromatogr A
, vol.1082
, pp. 6-14
-
-
Gjerde, J.1
Kisanga, E.R.2
Hauglid, M.3
Holm, P.I.4
Mellgren, G.5
Lien, E.A.6
-
27
-
-
0029987948
-
Age-related difference in tamoxifen disposition
-
8612384 10.1016/S0009-9236(96)90108-3 1:CAS:528:DyaK28XjtVyrtrc%3D
-
Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E, Namer M, Ferrero JM, Milano G (1996) Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59:401-410
-
(1996)
Clin Pharmacol Ther
, vol.59
, pp. 401-410
-
-
Peyrade, F.1
Frenay, M.2
Etienne, M.C.3
Ruch, F.4
Guillemare, C.5
Francois, E.6
Namer, M.7
Ferrero, J.M.8
Milano, G.9
-
28
-
-
0242331677
-
Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients
-
10.1089/154099903322447765
-
Sheth HR, Lord G, Tkaczuk K, Danton M, Lewis LM, Langenberg P, Lim CK, Flaws JA (2003) Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients. J Womens Health (Larchmt) 12:799-808
-
(2003)
J Womens Health (Larchmt)
, vol.12
, pp. 799-808
-
-
Sheth, H.R.1
Lord, G.2
Tkaczuk, K.3
Danton, M.4
Lewis, L.M.5
Langenberg, P.6
Lim, C.K.7
Flaws, J.A.8
-
29
-
-
28444498289
-
Excretion of hydroxylated metabolites of tamoxifen in human bile and urine
-
16334131 1:CAS:528:DC%2BD2MXhtlWgtL7J
-
Kisanga ER, Mellgren G, Lien EA (2005) Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Res 25:4487-4492
-
(2005)
Anticancer Res
, vol.25
, pp. 4487-4492
-
-
Kisanga, E.R.1
Mellgren, G.2
Lien, E.A.3
-
30
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
1244564 10.1159/000180580 1:STN:280:DyaE28%2FnsF2isw%3D%3D
-
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
31
-
-
84875988706
-
CYP2D6 and adjuvant tamoxifen: Possible differences of outcome in pre- and post-menopausal patients
-
10.2217/pgs.13.47 23570465 10.2217/pgs.13.47 1:CAS:528: DC%2BC3sXlsF2itbc%3D
-
Margolin S, Lindh JD, Thoren L, Xie H, Koukel L, Dahl ML, Eliasson E (2013) CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. Pharmacogenomics 14:613-622. doi: 10.2217/pgs.13.47
-
(2013)
Pharmacogenomics
, vol.14
, pp. 613-622
-
-
Margolin, S.1
Lindh, J.D.2
Thoren, L.3
Xie, H.4
Koukel, L.5
Dahl, M.L.6
Eliasson, E.7
-
32
-
-
84868205777
-
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
-
22562123 10.1007/s10549-012-2074-9 1:CAS:528:DC%2BC38XhtVOhsLnE
-
Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA (2012) Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res Treat 134:693-700
-
(2012)
Breast Cancer Res Treat
, vol.134
, pp. 693-700
-
-
Gjerde, J.1
Gandini, S.2
Guerrieri-Gonzaga, A.3
Haugan Moi, L.L.4
Aristarco, V.5
Mellgren, G.6
Decensi, A.7
Lien, E.A.8
-
33
-
-
0038467378
-
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
-
12783932 10.1093/jnci/95.11.779 1:CAS:528:DC%2BD3sXksVWqtr8%3D
-
Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779-790
-
(2003)
J Natl Cancer Inst
, vol.95
, pp. 779-790
-
-
Decensi, A.1
Robertson, C.2
Viale, G.3
Pigatto, F.4
Johansson, H.5
Kisanga, E.R.6
Veronesi, P.7
Torrisi, R.8
Cazzaniga, M.9
Mora, S.10
Sandri, M.T.11
Pelosi, G.12
Luini, A.13
Goldhirsch, A.14
Lien, E.A.15
Veronesi, U.16
-
34
-
-
84865289242
-
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
-
22703232 10.1186/1471-2407-12-247 1:CAS:528:DC%2BC38XhsFyhu7jK
-
Moi LL, Flageng MH, Gjerde J, Madsen A, Rost TH, Gudbrandsen OA, Lien EA, Mellgren G (2012) Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer 12:247-258
-
(2012)
BMC Cancer
, vol.12
, pp. 247-258
-
-
Moi, L.L.1
Flageng, M.H.2
Gjerde, J.3
Madsen, A.4
Rost, T.H.5
Gudbrandsen, O.A.6
Lien, E.A.7
Mellgren, G.8
-
35
-
-
79955485361
-
Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes
-
21430657 10.1038/clpt.2011.32 1:CAS:528:DC%2BC3MXltVGnt74%3D
-
Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718-725
-
(2011)
Clin Pharmacol Ther
, vol.89
, pp. 718-725
-
-
Madlensky, L.1
Natarajan, L.2
Tchu, S.3
Pu, M.4
Mortimer, J.5
Flatt, S.W.6
Nikoloff, D.M.7
Hillman, G.8
Fontecha, M.R.9
Lawrence, H.J.10
Parker, B.A.11
Wu, A.H.12
Pierce, J.P.13
-
36
-
-
84876563989
-
CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
-
23476897 10.1186/2193-1801-2-52
-
Love RR, Desta Z, Flockhart D, Skaar T, Ogburn ET, Ramamoorthy A, Uy GB, Laudico AV, Van Dinh N, Quang LH, Van To T, Young GS, Hade E, Jarjoura D (2013) CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer. SpringerPlus 2:52-56
-
(2013)
SpringerPlus
, vol.2
, pp. 52-56
-
-
Love, R.R.1
Desta, Z.2
Flockhart, D.3
Skaar, T.4
Ogburn, E.T.5
Ramamoorthy, A.6
Uy, G.B.7
Laudico, A.V.8
Van Dinh, N.9
Quang, L.H.10
Van To, T.11
Young, G.S.12
Hade, E.13
Jarjoura, D.14
-
37
-
-
84877578215
-
Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts
-
23605084 10.1007/s10549-013-2530-1 1:CAS:528:DC%2BC3sXnsVWhs7k%3D
-
Gong IY, Teft WA, Ly J, Chen YH, Alicke B, Kim RB, Choo EF (2013) Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res Treat 139:61-69
-
(2013)
Breast Cancer Res Treat
, vol.139
, pp. 61-69
-
-
Gong, I.Y.1
Teft, W.A.2
Ly, J.3
Chen, Y.H.4
Alicke, B.5
Kim, R.B.6
Choo, E.F.7
-
38
-
-
26844529410
-
Optical coherence tomography findings in tamoxifen retinopathy
-
16226541 10.1016/j.ajo.2005.04.042
-
Gualino V, Cohen SY, Delyfer MN, Sahel JA, Gaudric A (2005) Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol 140:757-758
-
(2005)
Am J Ophthalmol
, vol.140
, pp. 757-758
-
-
Gualino, V.1
Cohen, S.Y.2
Delyfer, M.N.3
Sahel, J.A.4
Gaudric, A.5
-
39
-
-
42649102676
-
Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma
-
18505063
-
Lindahl B, Andolf E, Ingvar C, Ranstam J, Willen R (2008) Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma. Anticancer Res 28:1259-1262
-
(2008)
Anticancer Res
, vol.28
, pp. 1259-1262
-
-
Lindahl, B.1
Andolf, E.2
Ingvar, C.3
Ranstam, J.4
Willen, R.5
-
40
-
-
84856164078
-
Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
-
21947681 10.1007/s10549-011-1777-7 1:CAS:528:DC%2BC3MXhs1ajt73L
-
Kiyotani K, Mushiroda T, Imamura CK, Tanigawara Y, Hosono N, Kubo M, Sasa M, Nakamura Y, Zembutsu H (2012) Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat 131:137-145
-
(2012)
Breast Cancer Res Treat
, vol.131
, pp. 137-145
-
-
Kiyotani, K.1
Mushiroda, T.2
Imamura, C.K.3
Tanigawara, Y.4
Hosono, N.5
Kubo, M.6
Sasa, M.7
Nakamura, Y.8
Zembutsu, H.9
-
41
-
-
84874745627
-
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
-
for the Adjuvant Tamoxifen: Longer Against Shorter Collaborative G 10.1016/S0140-6736(12)61963-1
-
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen: Longer Against Shorter Collaborative G (2012) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: aTLAS, a randomised trial. Lancet 381:805-816
-
(2012)
Lancet
, vol.381
, pp. 805-816
-
-
Davies, C.1
Pan, H.2
Godwin, J.3
Gray, R.4
Arriagada, R.5
Raina, V.6
Abraham, M.7
Alencar, V.H.8
Badran, A.9
Bonfill, X.10
Bradbury, J.11
Clarke, M.12
Collins, R.13
Davis, S.R.14
Delmestri, A.15
Forbes, J.F.16
Haddad, P.17
Hou, M.F.18
Inbar, M.19
Khaled, H.20
Kielanowska, J.21
Kwan, W.H.22
Mathew, B.S.23
Mittra, I.24
Muller, B.25
Nicolucci, A.26
Peralta, O.27
Pernas, F.28
Petruzelka, L.29
Pienkowski, T.30
Radhika, R.31
Rajan, B.32
Rubach, M.T.33
Tort, S.34
Urrutia, G.35
Valentini, M.36
Wang, Y.37
Peto, R.38
more..
-
42
-
-
79959884829
-
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
-
21335417 10.1093/annonc/mdq738 1:STN:280:DC%2BC3MbktlyqsA%3D%3D
-
Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Lang I, Thurlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS (2011) Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 22:2201-2207
-
(2011)
Ann Oncol
, vol.22
, pp. 2201-2207
-
-
Viale, G.1
Regan, M.M.2
Dell'Orto, P.3
Mastropasqua, M.G.4
Maiorano, E.5
Rasmussen, B.B.6
Macgrogan, G.7
Forbes, J.F.8
Paridaens, R.J.9
Colleoni, M.10
Lang, I.11
Thurlimann, B.12
Mouridsen, H.13
Mauriac, L.14
Gelber, R.D.15
Price, K.N.16
Goldhirsch, A.17
Gusterson, B.A.18
Coates, A.S.19
-
43
-
-
33847373003
-
Early discontinuation of tamoxifen: A lesson for oncologists
-
17243168 10.1002/cncr.22485 1:CAS:528:DC%2BD2sXjsVKns7s%3D
-
Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832-839
-
(2007)
Cancer
, vol.109
, pp. 832-839
-
-
Barron, T.I.1
Connolly, R.2
Bennett, K.3
Feely, J.4
Kennedy, M.J.5
|